CLAIMS

1. A pharmaceutical formulation, comprising:

a core layer containing metformin or a pharmaceutically acceptable salt thereof as an active ingredient; and

an outer layer containing lobeglitazone or a pharmaceutically acceptable salt thereof as an active ingredient;

wherein the outer layer comprises a binder having a viscosity of 6 mPa.s or less and triethyl citrate as a plasticizer.

2. The pharmaceutical formulation of claim 1, wherein the metformin or the pharmaceutically acceptable salt thereof is present in an amount of 60 to 80 wt% based on a total weight of the core layer.

3. The pharmaceutical formulation of claim 1, wherein the core layer comprises a water-soluble polymer.

4. The pharmaceutical formulation of claim 3, wherein the water-soluble polymer is selected from the group consisting of hydroxypropyl methylcellulose, ethyl cellulose, methyl cellulose, hydroxypropylcellulose, polyvinyl pyrrolidone, polymethacrylate, and mixtures thereof.

5. The pharmaceutical formulation of claim 3, wherein the water-soluble polymer is present in an amount of 15 to 25 wt% based on a total weight of the core layer.

6. The pharmaceutical formulation of claim 1, wherein the lobeglitazone or the pharmaceutically acceptable salt thereof is present in an amount of 0.1 to 2.0 wt% based on a total weight of the outer layer.

7. The pharmaceutical formulation of claim 1, wherein the binder is selected from the group consisting of hydroxypropyl methylcellulose, polyvinyl pyrrolidone, lactose, and mixtures thereof.

8. The pharmaceutical formulation of claim 1, wherein the triethyl citrate is present in an amount of 5 to 10 wt% based on a total weight of the outer layer.

9. The pharmaceutical formulation of claim 1, further comprising an inert intermediate layer between the core layer and the outer layer.